Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This trial is testing a drug called inotuzumab ozogamicin — a targeted antibody therapy — given to patients after a stem cell (bone marrow) transplant for a type of blood cancer called acute lymphoblastic leukemia (ALL), to try to eliminate any remaining cancer cells and prevent relapse. **You may be eligible if...** - You have been diagnosed with CD22-positive ALL (a specific type of leukemia) - You have already received a stem cell transplant from a donor for your leukemia - You are between 40 and 100 days after your transplant - There are still detectable leukemia cells in your body (minimal residual disease) OR you were in second or third remission at the time of transplant - Your blood counts have recovered sufficiently after the transplant - You are able to function reasonably well in daily life (ECOG performance status under 2) - You are willing and able to sign an informed consent **You may NOT be eligible if...** - You are more than 100 days past your transplant - Your blood counts have not recovered enough - You have significant liver, kidney, or other organ problems - You have active graft-versus-host disease (a complication where donor cells attack your body) Talk to your doctor to see if this trial is right for you.